Cinchocaine: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{drugbox
{{Drugbox
| IUPAC_name = 2-butoxy-''N''-(2-diethylaminoethyl) quinoline-4-carboxamide
| Watchedfields = changed
| image =
| verifiedrevid = 460037677
| IUPAC_name = 2-butoxy-''N''-[2-(diethylamino)ethyl]quinoline-4-carboxamide
| image = Cinchocaine.svg
| image2 = Cinchocaine 3D ball-and-stick.png
 
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|cinchocaine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = OTC
| legal_status = 
| routes_of_administration = topical, intravenous (equine euthanasia)
 
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
 
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 85-79-0
| CAS_number = 85-79-0
| ATC_prefix = C05
| ATC_prefix = C05
| ATC_suffix = AD04  
| ATC_suffix = AD04
| ATC_supplemental = {{ATC|D04|AB02}} {{ATC|N01|BB06}} {{ATC|S01|HA06}}
| ATC_supplemental = {{ATC|D04|AB02}} {{ATC|N01|BB06}} {{ATC|S01|HA06}} {{ATC|S02|DA04}}
| PubChem = 3025
| PubChem = 3025
| DrugBank = APRD00915
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| C = 20 | H = 29 | N = 3 | O = 2
| DrugBank = DB00527
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2917
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = L6JW2TJG99
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00733
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 247956
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1086
 
<!--Chemical data-->
| C=20 | H=29 | N=3 | O=2
| molecular_weight = 343.463 g/mol
| molecular_weight = 343.463 g/mol
| bioavailability =  
| smiles = O=C(c1c2ccccc2nc(OCCCC)c1)NCCN(CC)CC
| protein_bound =  
| InChI = 1/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
| metabolism =  
| InChIKey = PUFQVTATUTYEAL-UHFFFAOYAU
| elimination_half-life =  
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| excretion =
| StdInChI = 1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| pregnancy_US = <!-- A / B / C / D / X -->
| StdInChIKey = PUFQVTATUTYEAL-UHFFFAOYSA-N
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =  
| routes_of_administration =  
}}
}}
'''Cinchocaine''' ([[International Nonproprietary Name|INN]]/[[British Approved Name|BAN]]) or '''dibucaine''' ([[United States Adopted Name|USAN]]) is an [[amide]] [[local anesthetic]]. Among the most potent and toxic of the long-acting local anesthetics, current use of cinchocaine is generally restricted to spinal and topical anesthesia.<ref>Martindale, The Extra Pharmacopoeia, 30th ed, p1006</ref><ref>[http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?mode=&term=Dibucaine Dibucaine]</ref> It is sold under the brand names '''Cincain''', '''Nupercainal''', '''Nupercaine''' and '''Sovcaine'''.
==Medical use==
Cinchocaine is the active ingredient in some topical hemorrhoid creams such as [[Proctosedyl]]. It is also a component of the [[veterinary]] drug '''Somulose''', used for [[animal euthanasia|euthanasia]] of [[horse]]s and [[cattle]].
==Physical properties==
Cinchocaine is relatively [[insoluble]] in [[alkaline]] aquatic solutions.


==Overview==
==See also==
'''Cinchocaine''' (or '''Dibucaine''') is an [[amide]] [[local anesthetic]].  It is the active ingredient in some topical hemorrhoid creams.
* [[Dibucaine number]]


It is also a component of the [[veterinary]] drug '''Somulose''', used for [[animal euthanasia|euthanasia]] of horses and cattle.
==References==
{{reflist}}


==External links==
==Further reading==
* {{cite journal | author = Abdel-Ghani N, Youssef A, Awady M | title = Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry. | journal = Farmaco | volume = 60 | issue = 5 | pages = 419-24 | year = 2005 | id = PMID 15910814}}
* {{cite journal | author = Abdel-Ghani N, Youssef A, Awady M | title = Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry. | journal = Farmaco | volume = 60 | issue = 5 | pages = 419–24 | year = 2005 | pmid = 15910814 | doi = 10.1016/j.farmac.2005.03.001}}
* {{cite journal | author = Souto-Padron T, Lima AP, de Oliveira Ribeiro R. | title = Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi. | journal = Parasitol Res | volume = | issue = | pages = | year = 2006 | id = PMID 16612626}}
* {{cite journal | author = Souto-Padron T, Lima AP, de Oliveira Ribeiro R. | title = Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi. | journal = Parasitol Res | volume = 99| issue = 4| pages = 317–20| year = 2006 | pmid = 16612626 | doi = 10.1007/s00436-006-0192-1}}
* {{cite journal | author = Nounou M, El-Khordagui L, Khalafallah N | title = Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. | journal = Acta Pol Pharm | volume = 62 | issue = 5 | pages = 369-79 | year = | id = PMID 16459486}}
* {{cite journal | author = Nounou M, El-Khordagui L, Khalafallah N | title = Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. | journal = Acta Pol Pharm | volume = 62 | issue = 5 | pages = 369–79 | year = 2005| pmid = 16459486}}
* {{cite journal | author = Aroti,A.;Leontidis, E. | title =  Simultaneous Determination of the Ionization Constant and the Solubility of Sparingly Soluble Drug Substances. A Physical Chemistry Experiment . | journal = Journal of Chemical Education| volume = 78 | issue =  6 | pages = 786–788 | year = 2001 | doi = 10.1021/ed078p786}}


{{Vasoprotectives}}
{{Vasoprotectives}}
{{Antipruritics}}
{{Antipruritics}}
{{local anesthetics}}
{{local anesthetics}}
{{dermatologic-drug-stub}}
{{nervous-system-drug-stub}}


[[Category:Local anesthetics]]
[[Category:Local anesthetics]]
 
[[Category:Quinolines]]
{{WikiDoc Help Menu}}
[[Category:Phenol ethers]]
 
[[Category:Amides]]
{{WS}}

Revision as of 12:43, 13 April 2015

Cinchocaine
File:Cinchocaine.svg
File:Cinchocaine 3D ball-and-stick.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
topical, intravenous (equine euthanasia)
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H29N3O2
Molar mass343.463 g/mol
3D model (JSmol)
  (verify)

Cinchocaine (INN/BAN) or dibucaine (USAN) is an amide local anesthetic. Among the most potent and toxic of the long-acting local anesthetics, current use of cinchocaine is generally restricted to spinal and topical anesthesia.[1][2] It is sold under the brand names Cincain, Nupercainal, Nupercaine and Sovcaine.

Medical use

Cinchocaine is the active ingredient in some topical hemorrhoid creams such as Proctosedyl. It is also a component of the veterinary drug Somulose, used for euthanasia of horses and cattle.

Physical properties

Cinchocaine is relatively insoluble in alkaline aquatic solutions.

See also

References

  1. Martindale, The Extra Pharmacopoeia, 30th ed, p1006
  2. Dibucaine

Further reading

  • Abdel-Ghani N, Youssef A, Awady M (2005). "Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry". Farmaco. 60 (5): 419–24. doi:10.1016/j.farmac.2005.03.001. PMID 15910814.
  • Souto-Padron T, Lima AP, de Oliveira Ribeiro R. (2006). "Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi". Parasitol Res. 99 (4): 317–20. doi:10.1007/s00436-006-0192-1. PMID 16612626.
  • Nounou M, El-Khordagui L, Khalafallah N (2005). "Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles". Acta Pol Pharm. 62 (5): 369–79. PMID 16459486.
  • Aroti,A.;Leontidis, E. (2001). "Simultaneous Determination of the Ionization Constant and the Solubility of Sparingly Soluble Drug Substances. A Physical Chemistry Experiment". Journal of Chemical Education. 78 (6): 786–788. doi:10.1021/ed078p786.

Template:Vasoprotectives Template:Antipruritics

Template:Dermatologic-drug-stub Template:Nervous-system-drug-stub